High mobility group box 1 promotes radioresistance in esophageal squamous cell carcinoma cell lines by modulating autophagy

Cell Death and Disease - Tập 10 Số 2
Hongbing Ma1, Shuyu Zheng1, Xiaozhi Zhang2, Tuotuo Gong2, Xin Lv3, Shenbo Fu2, Shuqun Zhang4, Xiaoran Yin4, Jingcan Hao5, Changyou Shan4, Shan Huang1
1Department of Radiation Oncology, Second Affiliated Hospital, Xi'an Jiaotong University, 710004, Xi'an, China
2Department of Radiation Oncology, First Affiliated Hospital, Xi'an Jiaotong University, 710061, Xi'an, China
3Department of Respiratory and Clinical Care Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, 710004, Xi'an, China
4Department of Oncology, Second Affiliated Hospital, Xi'an Jiaotong University, 710004, Xi'an, China
5Department of Cancer Center, First Affiliated Hospital, Xi'an Jiaotong University, 710061, Xi'an, China

Tóm tắt

AbstractResistance to radiotherapy results in relapse and treatment failure in locally advanced esophageal squamous cell carcinoma (ESCC). High mobility group box 1 (HMGB1) is reported to be associated with the radioresistance in bladder and breast cancer. However, the role of HMGB1 in the radiotherapy response in ESCC has not been fully elucidated. Here, we investigated the role of HMGB1 to radioresistance in ESCC clinical samples and cell lines. We found that HMGB1 expression was associated with tumor recurrence after postoperative radiotherapy in locally advanced ESCC patients. HMGB1 knockdown in ESCC cells resulted in increased radiosensitivity both in vitro and in vivo. Autophagy level was found depressed in HMGB1 inhibition cells and activation of autophagy brought back cell’s radioresistance. Our results demonstrate that HMGB1 activate autophagy and consequently promote radioresistance. HMGB1 may be used as a predictor of poor response to radiotherapy in ESCC patients. Our finding also highlights the importance of the utility of HMGB1 in ESCC radiosensitization.

Từ khóa


Tài liệu tham khảo

Fitzmaurice, C. et al. The global burden of cancer 2013. JAMA Oncol. 1, 505–527 (2015).

Liang, H., Fan, J. H. & Qiao, Y. L. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol. Med. 14, 33–41 (2017).

Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400–412 (2013).

Teniere, P., Hay, J. M., Fingerhut, A. & Fagniez, P. L. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg., Gynecol. Obstet. 173, 123–130 (1991).

Fok, M., Sham, J. S., Choy, D., Cheng, S. W. & Wong, J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 113, 138–147 (1993).

Chen, J. et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann. Thorac. Surg. 90, 435–442 (2010).

Xiao, Z. F. et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann. Thorac. Surg. 75, 331–336 (2003).

Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331–342 (2005).

Shrivastava, S. et al. The role of HMGB1 in radioresistance of bladder cancer. Mol. Cancer Ther. 15, 471–479 (2016).

Ke, S. et al. Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J. Oncol. 46, 1051–1058 (2015).

Chuangui, C., Peng, T. & Zhentao, Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol. Oncol. Res. 18, 1021–1027 (2012).

Chen, C., Cui, L., Tang, P. & Yu, Z. Clinical significance of serum high-mobility group box 1 detection in esophageal squamous cell carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 16, 838–841 (2013).

Tang, D. et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881–892 (2010).

Chen, X. et al. Autophagy enhanced the radioresistance of non-small cell lung cancer by regulating ROS level under hypoxia condition. Int J. Radiat. Biol. 93, 764–770 (2017).

Chaachouay, H. et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother. Oncol. 99, 287–292 (2011).

Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition. Autophagy 12, 1–222 (2016).

Hongo, K. et al. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study. World J. Surg. Oncol. 13, 7 (2015).

Machado, L. R. et al. High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget 8, 101215–101223 (2017).

Wang, F., et al. SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy. Clin. Cancer Res. 24, 3176–3185 (2018).

Tao, H., et al. Autophagy inhibition enhances radiosensitivity of Eca109 cells via the mitochondrial apoptosis pathway. Int. J. Oncol. 52, 1853–1862 (2018).

Sharma, K., Goehe, R., Beckta, J. M., Valerie, K. & Gewirtz, D. A. Autophagy and radiosensitization in cancer. EXCLI J. 13, 178–191 (2014).

Rice, T. W., Ishwaran, H., Ferguson, M. K., Blackstone, E. H. & Goldstraw, P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J. Thorac. Oncol. 12, 36–42 (2017).

Gong, T. et al. PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis. Mol. Carcinog. 56, 2610–2619 (2017).

Huang, S. et al. Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Dis. Esophagus. 26, 823–831 (2013).

Remmele, W. & Stegner, H. E. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8, 138–140 (1987).

Thông tin
Thông tin xuất bản

Cell Death and Disease

Tập 10 Số 2

Thông tin tác giả